fibrinolysin and desoxyribonuclease combined [bovine], with chloramphenicol (Elase-chloromycetin)
fibrinolysin and desoxyribonuclease combined [bovine], with chloramphenicol is an FDA-licensed reference biologic from Parke-Davis, a Division of Pfizer Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
1964
Reference approved
Reference product
Elase-chloromycetin fibrinolysin and desoxyribonuclease combined [bovine], with chloramphenicol
Parke-Davis, a Division of Pfizer Inc.
- Approved
- Apr 01, 1964
- Marketing
- Disc
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for fibrinolysin and desoxyribonuclease combined [bovine], with chloramphenicol, in chronological order.
Reference approval
Approval date of the reference fibrinolysin and desoxyribonuclease combined [bovine], with chloramphenicol product.
63 yr 1 mo ago
Frequently asked questions
Are there biosimilars approved for fibrinolysin and desoxyribonuclease combined [bovine], with chloramphenicol (Elase-chloromycetin)?
No 351(k) biosimilars or interchangeable biosimilars referencing fibrinolysin and desoxyribonuclease combined [bovine], with chloramphenicol are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.